Related Experiment Video
Updated: Feb 14, 2026

Ileectomy-induced Bile Overaccumulation in Mouse Intestine
Published on: August 21, 2017
ADAM17 is required for EGF-R-induced intestinal tumors via IL-6 trans-signaling
Stefanie Schmidt1, Neele Schumacher1, Jeanette Schwarz1
1Biochemisches Institut, Christian Albrechts Universität Kiel, Kiel, Germany.
Abstract:
Colorectal cancer is treated with antibodies blocking epidermal growth factor receptor (EGF-R), but therapeutic success is limited. EGF-R is stimulated by soluble ligands, which are derived from transmembrane precursors by ADAM17-mediated proteolytic cleavage. In mouse intestinal cancer models in the absence of ADAM17, tumorigenesis was almost completely inhibited, and the few remaining tumors were of low-grade dysplasia. RNA sequencing analysis demonstrated down-regulation of STAT3 and Wnt pathway components. Because EGF-R on myeloid cells, but not on intestinal epithelial cells, is required for intestinal cancer and because IL-6 is induced via EGF-R stimulation, we analyzed the role of IL-6 signaling. Tumor formation was equally impaired in IL-6-/- mice and sgp130Fc transgenic mice, in which only trans-signaling via soluble IL-6R is abrogated. ADAM17 is needed for EGF-R-mediated induction of IL-6 synthesis, which via IL-6 trans-signaling induces β-catenin-dependent tumorigenesis. Our data reveal the possibility of a novel strategy for treatment of colorectal cancer that could circumvent intrinsic and acquired resistance to EGF-R blockade.
Insights
ADAM17 inhibition significantly reduces colorectal cancer growth by blocking epidermal growth factor receptor (EGF-R) signaling. This pathway involves IL-6 trans-signaling, offering a new therapeutic strategy against EGF-R blockade resistance.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Colorectal cancer (CRC) treatment involves epidermal growth factor receptor (EGF-R) antibodies, but resistance limits efficacy.
- EGF-R activation by soluble ligands involves ADAM17-mediated cleavage of its precursors.
- EGF-R signaling on myeloid cells, not epithelial cells, drives intestinal tumorigenesis.
Purpose of the Study:
- To investigate the role of ADAM17 and IL-6 signaling in colorectal cancer development.
- To explore a novel therapeutic strategy targeting ADAM17-mediated pathways.
Main Methods:
- Utilized mouse intestinal cancer models with and without ADAM17.
- Performed RNA sequencing to analyze gene expression changes.
- Assessed tumor formation in IL-6 knockout and sgp130Fc transgenic mice.
Main Results:
- Absence of ADAM17 nearly abolished tumorigenesis and reduced tumor grade in mouse models.
- RNA sequencing revealed downregulation of STAT3 and Wnt pathway components.
- Impaired tumor formation was observed in IL-6 deficient and IL-6 trans-signaling blocked mice.
- ADAM17 mediates EGF-R-induced IL-6 synthesis, crucial for β-catenin-dependent tumorigenesis.
Conclusions:
- ADAM17-dependent IL-6 trans-signaling is a key driver of colorectal tumorigenesis.
- Targeting ADAM17 or IL-6 trans-signaling presents a promising therapeutic approach for CRC.
- This strategy may overcome resistance to current EGF-R blockade therapies.
Related Concept Videos
Energy-requiring Steps of Glycolysis
Role Of Notch Signalling In Intestinal Stem Cell Renewal
Direct cell-to-cell contact is needed for the activation of Notch signaling. The signal is initiated when a notch ligand binds to a receptor on an adjacent cell, also...
Anatomy of the Intestines
Small Intestines
The small intestine is an ~7 meter-long tube with an inner diameter of just 2.5 cm. Since most nutrients are absorbed here, the inner lining of the...
Requirements for Human Life
Oxygen
Atmospheric air is only about 20 percent oxygen, but that oxygen is a key component of the chemical reactions that keep the body alive, including the reactions that produce ATP. Brain cells are susceptible to a lack of oxygen because they require a...
Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal
Proteins: Dietary Sources and Requirements

